Open AccessOrganization of lipid centers operation in the Russian Federation — new opportunities
Author(s) -
M. Ezhov,
О. Л. Барбараш,
М. И. Воевода,
В. С. Гуревич,
Н. Н. Везикова,
Д. И. Садыкова,
И. В. Сергиенко,
В. В. Кашталап,
А. Н. Мешков,
Д. В. Дупляков,
А. А. Соколов,
С. А. Бойцов
Publication year - 2021
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2021-4489
Subject(s) - medicine , dyslipidemia , russian federation , familial hypercholesterolemia , christian ministry , medical prescription , family medicine , lipid metabolism disorder , population , lipid metabolism , intensive care medicine , environmental health , cholesterol , blood lipids , pharmacology , disease , philosophy , theology , business , economic policy
Project of the Russian National Atherosclerosis Society In 2016, Guidelines on the medical care organization to the patients with hereditary atherogenic lipid disorders in the regions of Russia were published, which described and presented the principles of routing patients with hereditary dyslipidemia and the organization of medical care for them within the current regulatory documents. In December 2018, the Russian Ministry of Health approved clinical guidelines for the diagnosis and treatment of familial hypercholesterolemia. Thus, persons with a severe hereditary dyslipidemia were able to get free medication with expensive lipid-lowering drugs and receive apheresis. Following the European ones, the Russian guidelines on the management of lipid metabolism disorders were updated: lower target low density lipoprotein cholesterol levels were adopted. In the Russian population, there is a high prevalence of hypercholesterolemia, including familial monogenic and polygenic types. Therefore, timely detection and routing to a lipid center or an office to a specialist (cardiologist, lipidologist), adequate and modern prescription of lipid-lowering therapy will make an important contribution not only to secondary, but also to primary prevention of atherosclerotic cardiovascular complications.